11,667 Shares in Evoke Pharma, Inc. (NASDAQ:EVOK) Purchased by Corsair Capital Management L.P.

Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a research report on Wednesday, November 20th. They set a “sell” rating on the stock.

Evoke Pharma Trading Up 0.9 %

Shares of EVOK stock opened at $4.39 on Wednesday. Evoke Pharma, Inc. has a 1 year low of $3.54 and a 1 year high of $17.40. The stock has a 50 day simple moving average of $5.15 and a 200 day simple moving average of $5.44.

Evoke Pharma Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.